Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 24768112

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2014 Jul 26
First author
Brose MS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2014 Jul 26;384(9940):286-8. doi: 10.1016/S0140-6736(14)60663-2.
    note
    Source null
    related pmid
    24768111
    relationship
    Comment in
  2. citation
    Lancet. 2015 Jan 17;385(9964):227-8. doi: 10.1016/S0140-6736(15)60054-X.
    note
    Source null
    related pmid
    25706704
    relationship
    Comment in
  3. citation
    Lancet. 2015 Jan 17;385(9964):227. doi: 10.1016/S0140-6736(15)60053-8.
    note
    Source null
    related pmid
    25706705
    relationship
    Comment in
  4. citation
    Lancet. 2015 Jan 17;385(9964):228-9. doi: 10.1016/S0140-6736(15)60056-3.
    note
    Source null
    related pmid
    25706706
    relationship
    Comment in
  5. citation
    Lancet. 2015 Jan 17;385(9964):228. doi: 10.1016/S0140-6736(15)60055-1.
    note
    Source null
    related pmid
    25706707
    relationship
    Comment in

Authors and identifiers

  1. name
    Brose MS
    type
    Author
  2. name
    Nutting CM
    type
    Author
  3. name
    Jarzab B
    type
    Author
  4. name
    Elisei R
    type
    Author
  5. name
    Siena S
    type
    Author
  6. name
    Bastholt L
    type
    Author
  7. name
    de la Fouchardiere C
    type
    Author
  8. name
    Pacini F
    type
    Author
  9. name
    Paschke R
    type
    Author
  10. name
    Shong YK
    type
    Author
  11. name
    Sherman SI
    type
    Author
  12. name
    Smit JW
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Brose MS
    type
    Author
  2. name
    Nutting CM
    type
    Author
  3. name
    Jarzab B
    type
    Author
  4. name
    Elisei R
    type
    Author
  5. name
    Siena S
    type
    Author
  6. name
    Bastholt L
    type
    Author
  7. name
    de la Fouchardiere C
    type
    Author
  8. name
    Pacini F
    type
    Author
  9. name
    Paschke R
    type
    Author
  10. name
    Shong YK
    type
    Author
  11. name
    Sherman SI
    type
    Author
  12. name
    Smit JW
    type
    Author
bibliography ids
  1. nci-bib-085755f54a2b0afff9f54fa1
book metadata
content sha256
4b026100db5b850d2c65f9a3513c10c97590a15bd2b1d9612badd075b2c3b996
document type
citation
dois
  1. 10.1016/S0140-6736(14)60421-9
electronic publication date
display
2014 Apr 24
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:24768112
immutable id
pubmed:24768112@4b026100db5b850d2c65f9a3513c10c97590a15bd2b1d9612badd075b2c3b996
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
9940
name
Lancet (London, England)
nlm unique id
2985213R
pages
319-28
volume
384
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2014 Jul 26;384(9940):286-8. doi: 10.1016/S0140-6736(14)60663-2.
    note
    Source null
    related pmid
    24768111
    relationship
    Comment in
  2. citation
    Lancet. 2015 Jan 17;385(9964):227-8. doi: 10.1016/S0140-6736(15)60054-X.
    note
    Source null
    related pmid
    25706704
    relationship
    Comment in
  3. citation
    Lancet. 2015 Jan 17;385(9964):227. doi: 10.1016/S0140-6736(15)60053-8.
    note
    Source null
    related pmid
    25706705
    relationship
    Comment in
  4. citation
    Lancet. 2015 Jan 17;385(9964):228-9. doi: 10.1016/S0140-6736(15)60056-3.
    note
    Source null
    related pmid
    25706706
    relationship
    Comment in
  5. citation
    Lancet. 2015 Jan 17;385(9964):228. doi: 10.1016/S0140-6736(15)60055-1.
    note
    Source null
    related pmid
    25706707
    relationship
    Comment in
outcomes validated
false
pmid
24768112
provenance
batch id
063b6c38419f18d4021f
provider
NCBI PubMed ESummary
record sha256
aecd0d2cfb11a8e085bb04d8270b207754ff8d9b6cfe0aac6b2389bd9acc83bc
response sha256
5abcae41e9384a85f92695ef76b244ffd933f07a58a51082c160af8743d196ad
retrieved at
2026-09-09T23:47:02.607425+00:00
publication date
display
2014 Jul 26
precision
day
year
2014
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/24768112/
title
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Preserved source evidence · Not medical advice